Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
80°
Partly Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Allogene Therapeutics Inc
(NQ:
ALLO
)
2.610
+0.020 (+0.77%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Allogene Therapeutics Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Why Allogene Therapeutics Shares Are Seeing Blue Skies Today
January 24, 2023
Allogene Therapeutics Inc (NASDAQ: ALLO) shares are trading higher by 13.1% to $7.76 Tuesday morning after the company announced data from its Phase 1 UNIVERSAL trial of ALLO-715 has been published in...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 24, 2023
January 24, 2023
Via
Benzinga
Allogene Therapeutics Announces Publication in Nature Medicine of Data from its Phase 1 UNIVERSAL Study of ALLO-715 for the Treatment of Relapsed/Refractory Multiple Myeloma
January 24, 2023
ALLO-715 is the First Allogeneic anti-BCMA CAR T to Demonstrate Safety, Efficacy and Durability with Off-the-Shelf Convenience in Multiple Myeloma
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
5 Analysts Have This to Say About Allogene Therapeutics
January 24, 2023
Via
Benzinga
Amazon To Rally Over 28%? Here Are 10 Other Analyst Forecasts For Tuesday
January 24, 2023
Citigroup raised the price target for AT&T Inc. (NYSE: T) from $20 to $22. Citigroup analyst Michael Rollins maintained a Buy rating. AT&T shares fell 1% to $18.91 in pre-market trading.
Via
Benzinga
Yext, 1-800-Flowers.com And Other Big Stocks Moving Higher In Tuesday's Pre-Market Session
January 24, 2023
U.S. stock futures traded slightly lower this morning. Here are some big stocks recording gains in today’s pre-market trading session.
Via
Benzinga
Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences
January 17, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
WWE, AMTD Digital And Some Other Big Stocks Moving Higher In Friday's Pre-Market Session
January 06, 2023
U.S. stock futures traded mixed this morning. Here are some big stocks recording gains in today’s pre-market trading session. AMTD Digital Inc. (NYSE: HKD) shares surged 118.8% to $65.54 in pre-market...
Via
Benzinga
Expert Ratings for Allogene Therapeutics
September 22, 2022
Within the last quarter, Allogene Therapeutics (NASDAQ:ALLO) has observed the following analyst ratings:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2023
January 06, 2023
Via
Benzinga
Expert Ratings for Allogene Therapeutics
January 06, 2023
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
January 05, 2023
On Thursday, 63 companies set new 52-week lows.
Via
Benzinga
Allogene Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
January 05, 2023
Via
Benzinga
Allogene Appoints Zachary J. Roberts, M.D., Ph.D. as Executive Vice President of Research & Development
January 03, 2023
Cell Therapy Veteran and Former Kite Pharma Clinical Leader to Head Development of Expanding Portfolio of Allogeneic CAR T Product Candidates
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Crispr Stock In 2023: Will Down-In-The-Dumps Shares Sparkle Again In 2023?
December 22, 2022
Crispr and Vertex are working toward the first submissions for a CRISPR-based product.
Via
Investor's Business Daily
Top 10 Highest Short Interest Stocks And 10 With Highest Cost To Borrow: Where Do Carvana, MicroStrategy, Fisker And AMC Rank?
December 17, 2022
Investors often look for stocks with high short interest and a high cost to borrow, which could predict a potential short squeeze. New data shared by S3 Partners could signal which stocks investors are...
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
December 23, 2022
OnFriday, 143 stocks hit new 52-week lows.
Via
Benzinga
RH, HUYA, Bilibili And Some Other Big Stocks Moving Lower On Monday
December 12, 2022
U.S. stocks traded higher, with the Dow Jones jumping more than 200 points on Monday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 12, 2022
December 12, 2022
Via
Benzinga
Precigen's Overnight Cell Manufacturing Technology Could Offer Advanced AML Patients The Option Of Promising CAR-T Therapy
December 08, 2022
-Clinical Data Due Next Week at ASH-
Via
Benzinga
Allogene Therapeutics R&D Showcase Features Hematologic and Solid Tumor Advances Across its AlloCAR T™ Platform
November 29, 2022
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Unveils Novel Approach to Generate Engineered AlloCAR T™ Cells to Control Immune Rejection at the Annual Meeting of the Society for Immunotherapy of Cancer
November 10, 2022
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics To Host Research & Development Showcase and Participate in Five Upcoming Investor Conferences
November 09, 2022
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Announces Poster Presentation of Its Phase 1 UNIVERSAL Trial in Multiple Myeloma at the 64th Annual Meeting of the American Society of Hematology
November 03, 2022
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Reports Third Quarter 2022 Financial Results and Announces Investor R&D Showcase
November 02, 2022
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Overland Biopharm Completes Buildout of cGMP Manufacturing Facility in Shanghai to Support the Development of AlloCAR T™ Products in Asia
October 31, 2022
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics to Report Third Quarter 2022 Financial Results on November 2, 2022
October 26, 2022
Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Launches CAR T Together™, a First-of-its-Kind Initiative with Leading Oncologists Nationwide, Focused on Accelerating Development and Clinical Trial Recruitment for “Off-The-Shelf” Allogeneic Cell Therapy Investigational Products
October 11, 2022
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Initiates Industry’s First Allogeneic CAR T Phase 2 Trial
October 06, 2022
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.